Friday, December 9, 2011
FDA Approves Topical Oxybutynin for OAB
In Pharma News today the FDA approved an 3% topical once daily dose of oxybutynin gel, 84mg, to those who suffer from overactive bladder. OAB is essentially urinary urgency and frequency without any other associated condition and can be accompanied by urinary incontinence in some cases. Oxybutynin can be used to effectively treat this condition, which affects millions of people worldwide and has been shown to affect about 16% of adult men and women. Learn more about overactive bladder here.
Subscribe to:
Post Comments (Atom)
I wanted to thank you for this excellent read!! I definitely loved every little bit of it. I have you bookmarked your site to check out the new stuff you post.
ReplyDeletevitalhealthrecipes